Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

761.85 -15.40 (-1.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
Gapping S&P500 stocks in Monday's session ↗
Via Chartmill
Why Regeneron Pharmaceuticals’ Stock Is Climbing Premarket Today ↗
Via Stocktwits
News headline image
DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Forecasting The Future: 9 Analyst Projections For Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Regeneron's Libtayo Gains FDA Approval To Reduce Recurrence Risk In Skin Cancer Patients ↗
FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, based on Phase 3 trial data. 
Via Benzinga
News headline image
Investors Brace for Pullback as Short-Bias ETF Inflows Signal Growing Bearishness
A significant surge in capital flowing into short-bias Exchange-Traded Funds (ETFs) has sent a clear signal through the financial markets: investor sentiment is shifting towards caution and a potential... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out ↗
The small biotech company is looking to take on Regeneron and Sanofi's blockbuster, Dupixent. 
Via Investor's Business Daily
News headline image
Retail Buzz Builds Around Regeneron After FDA Clears Libtayo For High-Risk Skin Cancer; Traders Eye ‘Buying Opportunity’ ↗
The FDA’s approval of Libtayo was based on Phase 3 trial data showing a 68% reduction in the risk of recurrence or death in high-risk CSCC patients. 
Via Stocktwits
News headline image
Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September ↗
Results of the Resolve-AD trial with rezpegaldesleukin were better than expected. 
Via The Motley Fool
News headline image
A Look Into Regeneron Pharmaceuticals Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
Wednesday's session: top gainers and losers in the S&P500 index ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday. 
Via Chartmill
News headline image
Health Care Stocks Rally, Nike Beats The Street: What's Moving Markets Wednesday? ↗
Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps markets afloat. 
Via Benzinga
News headline image
Which S&P500 stocks are moving on Wednesday? ↗
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Nvidia, Amphenol, Lockheed Martin And A Health Care Stock On CNBC's 'Final Trades' ↗
Nvidia surges past 52-week high, surpasses $4.5 trillion market cap as tech companies invest in AI. Regeneron and Amphenol named as top trades. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Acuity, Lithium Americas, Rezolve AI, AES And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Beaten-Down Stocks to Buy and Hold for a Decade ↗
These biotechs should benefit from their innovative ways. 
Via The Motley Fool
News headline image
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by... 
Via MarketMinute
News headline image
1 Healthcare Stock with Exciting Potential and 2 We Ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This... 
Via StockStory
Topics Stocks
News headline image
FDA Expands Use Of Regeneron's Evkeeza To Infants With Rare Cholesterol Disorder ↗
The U.S. 
Via Benzinga
News headline image
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Regeneron (REGN) Shares Are Falling Today
Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.1% in the afternoon session after the company highlighted challenges, including regulatory approvals and competitive pressures, at a healthcare... 
Via StockStory
News headline image
Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch ↗
On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. 
Via Benzinga
News headline image
1 Safe-and-Steady Stock on Our Watchlist and 2 We Question
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
What Does the Market Think About Regeneron Pharmaceuticals? ↗
 
Via Benzinga
News headline image
Why Regeneron (REGN) Stock Is Down Today
Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.8% in the afternoon session after a court ruling in Australia dealt a blow to the company's efforts to block a competing version of its... 
Via StockStory
News headline image
Wall Street Pauses For A Breather, Small Caps Soar: What's Moving Markets Tuesday? ↗
Wall Street paused on Tuesday after three straight sessions of strong gains that pushed major large-cap indices to fresh records. 
Via Benzinga
News headline image
Discover which S&P500 stocks are making waves on Tuesday. ↗
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
News headline image
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection ↗
FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germany as the launch market. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.